Luc J J Derijks
Overview
Explore the profile of Luc J J Derijks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bayoumy A, Derijks L, Oldenburg B, de Boer N
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771479
The introduction of biological therapies has revolutionized inflammatory bowel disease (IBD) management. A critical consideration in developing these therapies is ensuring adequate drug concentrations at the site of action. While...
2.
Bayoumy A, Mulder C, de Boer N, Derijks L, Yang J, Schmiegelow K
Pediatr Blood Cancer
. 2024 Nov;
72(2):e31464.
PMID: 39616415
No abstract available.
3.
Deenen M, van Noordenburg A, Bouwens-Bijsterveld J, van Dijk M, Stapelbroek J, Derijks L, et al.
Pharmacogenomics J
. 2024 Nov;
24(6):39.
PMID: 39580429
Thiopurine drugs are cornerstone treatment for patients with inflammatory bowel disease (IBD). The most common adverse drug reaction is thiopurine-induced myelosuppression (TIM), that may partly be explained by the genetic...
4.
Bevers N, Keizer R, Wong D, Aliu A, Pierik M, Derijks L, et al.
Clin Pharmacokinet
. 2024 Mar;
63(4):529-538.
PMID: 38488984
Background And Objective: Efficacy of infliximab in children with inflammatory bowel disease can be enhanced when serum concentrations are measured and further dosing is adjusted to achieve and maintain a...
5.
Bevers N, Aliu A, Wong D, Winkens B, Vreugdenhil A, Pierik M, et al.
Therap Adv Gastroenterol
. 2024 Jan;
17:17562848231222337.
PMID: 38164362
Background: Exposure-response studies have shown that higher infliximab concentrations are associated with better outcomes in inflammatory bowel disease. There is little agreement about the optimal time to measure infliximab levels...
6.
van Aalen E, de Vries I, Hanckmann E, Stevens J, Romagnoli T, Derijks L, et al.
Sens Diagn
. 2023 Nov;
2(6):1492-1500.
PMID: 38013761
Therapeutic drug monitoring (TDM) of tumor necrosis factor-α (TNFα)-inhibitors adalimumab and infliximab is important to establish optimal drug dose and maximize treatment efficacy. Currently, TDM is primarily performed with ELISA...
7.
Deben D, Derijks L, van den Bosch B, Creemers R, van Nunen A, van Bodegraven A, et al.
Metabolites
. 2023 Oct;
13(10).
PMID: 37887379
Tioguanine is metabolised by fewer enzymatic steps compared to azathioprine and mercaptopurine, without generating 6-methylmercaptopurine ribonucleotides. However, thiopurine S-methyl transferase (TPMT) plays a role in early toxicity in all thiopurines....
8.
Crouwel F, Bayoumy A, Mulder C, Peters J, Boekema P, Derijks L, et al.
Inflamm Bowel Dis
. 2023 Sep;
30(9):1492-1499.
PMID: 37658804
Background: Currently thioguanine is solely used as treatment for inflammatory bowel disease after azathioprine and/or mercaptopurine failure. This study aimed to determine the safety, effectiveness, and 12-month drug survival of...
9.
de Klaver P, Keizer R, Ter Heine R, Smits L, Boekema P, Kuntzel I, et al.
Eur J Drug Metab Pharmacokinet
. 2023 Jun;
48(4):377-385.
PMID: 37322238
Background And Objective: Underdosing of adalimumab can result in non-response and poor disease control in patients with rheumatic disease or inflammatory bowel disease. In this pilot study we aimed to...
10.
Sivridas M, Creemers R, Wong D, Boekema P, Romkens T, Gilissen L, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986833
There are limited data on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients treated with vedolizumab (VDZ). Although an exposure-response relation has been demonstrated in the post-induction phase,...